Korro receives australian hrec approval and ctn clearance to initiate phase 1/2a clinical study (rewrite) of krro-110 for alpha-1 antitrypsin deficiency

-rewrite study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of krro-110
KRRO Ratings Summary
KRRO Quant Ranking